Rejuvenate Bio Announces Team Expansion with Appointments of Garrett Berry and Sophia Gee
Rejuvenate Bio Announces Team Expansion with Appointments of Garrett Berry and Sophia Gee
San Diego, CA – Rejuvenate Bio, a biotech company developing gene therapies for age-related diseases, announced today the appointments of Garrett Berry as Senior Director of Business Development and Sophia Gee as Chief of Staff.
“I’m thrilled to welcome Garrett and Sophia, as we continue to expand our team and advance our novel gene therapy for humans and canines with age-related disease,” said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. “Both executives bring invaluable expertise, as we continue to advance our pipeline to reverse aging and eliminate age-related diseases.”
Garrett Berry joined Rejuvenate Bio as Senior Director of Business Development. Prior to joining Rejuvenate Bio, Garrett was the Associate Director of Business Development at StrideBio. Garrett joined Stride as the first full-time employee, and during his tenure, he played an increasing role in all business development activities, driving licensing deals and strategic collaborations with CRISPR Therapeutics, Takeda, Sarepta, as well as with numerous additional companies and universities. Garrett holds a Ph.D. in Genetics & Molecular Biology from the University of North Carolina at Chapel Hill, where he studied the intracellular trafficking of adeno-associated virus.
Sophia Gee joined Rejuvenate Bio as Chief of Staff. Prior to joining the company, Sophia was Senior Manager of Business Operations at Biogen, supporting the Research and External Innovation functions. At Biogen, she worked closely with the SVPs and their leadership teams supporting Research Units, Development Units, and External Innovation. Prior to Biogen, she was a business analyst at Pfizer, where she supported the neuroscience, biotherapeutics, and inflammation & immunology groups in R&D. She was also a practice development specialist in the Debt Finance practice at law firm, Ropes & Gray LLP. Leveraging her broad experience across biotech and operations management, in her new role at Rejuvenate, she will be supporting the CEO Daniel Oliver in driving company-wide strategic and tactical projects. Sophia holds a B.S in Business Administration from Boston University.
About Rejuvenate Bio
Rejuvenate Bio is a spinout from the Wyss Institute at Harvard focused on reversing aging and eliminating age-related disease. Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to humans and canines suffering from age-related conditions. The company is developing a pipeline of therapies with applications in cardiac and metabolic disease across humans and dogs. The company raised a Series A financing in 2021 led by Kendall Capital Partners, Digitalis Ventures, KdT Ventures and V Capital. Rejuvenate Bio is based in San Diego for more information, visit www.rejuvenatebio.com.
Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com